Clinical trials: Leishmaniasis
Cutaneous Leishmaniasis
Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients
Cutaneous leishmaniasis (CL) is endemic in Israel and is caused by Leishmania major or Leishmania tropica. CL is usually a benign disease and limited to the skin.
- Trial name
- NCT02281669
- Testing
- Pentostam
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Sheba Medical Center
Leishmaniasis, Cutaneous
Treatment of Cutaneous Leishmaniasis With Meglumine Antimoniate Versus Meglumine Antimoniate and Allopurinol
Background: Cutaneous Leishmaniasis is a worldwide disease, endemic in over 88 countries, that has shown an increasing incidence over the last many decades.
- Trial name
- NCT00480883
- Testing
- meglumine antimoniate, allopurinol, meglumine antimoniate
- Where
- Pakistan
- Volunteers
- 400 people
- Sponsor
- Combined Military Hospital, Pakistan
Cutaneous Leishmaniasis
Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica
Cutaneous leishmaniasis is a parasitic skin lesion caused by different species of Leishmania and transmitted by the bite of infected sand flies.
- Trial name
- NCT00351520
- Testing
- Miltefose
- Where
- Iran
- Volunteers
- 148 people
- Sponsor
- Tehran University of Medical Sciences
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Leishmaniasis, Leptospirosis
Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases
Zoonoses and arboviroses refer to a group of diseases transmitted from animals to humans, either directly or indirectly (via mosquitoes, ticks or contact with contaminated environments).
- Conditions
- Leishmaniasis, Leptospirosis, Brucellosis, Q Fever
- Trial name
- SEZAM (NCT06859619)
- Testing
- Peripheral venous blood sample
- Where
- France
- Volunteers
- 183 people
- Sponsor
- University Hospital, Montpellier
Mucosal Leishmaniasis
Treatment of Mucosal Bolivian Leishmaniasis
The purpose of this protocol is to conduct a randomized comparison of the efficacy and tolerance of miltefosine, LAMB, and pentavalent antimony for the treatment of mucosal leishmaniasis.
- Trial name
- NCT04799236
- Testing
- Group 1: Miltefosine, Group 2: Pentavalent Antimony, Group 3: Liposomal amphotericin B
- Where
- Bolivia
- Volunteers
- 120 people
- Sponsor
- Fundacion Nacional de Dermatologia
Visceral Leishmaniasis, Cutaneous Leishmaniases
Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects
This study will evaluate how the test medicine DNDI-0690 is taken up and broken down by the body and will also look at the safety and tolerability of the test medicine after a single dose.
- Trial name
- NCT03929016
- Testing
- DNDI-0690
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Leishmaniasis, Effects of Immunotherapy
SCH708980 With and Without AmBisome for Visceral Leishmaniasis
Background: Visceral leishmaniasis (VL) is an infection caused by parasites carried by sand flies. The parasites cause fever, weight loss, and enlargement of the spleen and liver. They can also affect the blood and immune system.
- Trial name
- NCT01437020
- Testing
- SCH708980 Anti-IL-10 monoclonal, AmBisome
- Where
- 2 sites in India
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Post Kala Azar Dermal Leishmaniasis
Safety and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine With SSG for Patients With PKDL
A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of three injections of 10 µg LEISH-F2 + 25 µg MPL-SE given at 14-day intervals as an adjunct to standard…
- Trial name
- NCT00982774
- Testing
- LEISH-F2 + MPL-SE vaccine
- Where
- Sudan
- Volunteers
- 42 people
- Sponsor
- Access to Advanced Health Institute (AAHI)
Kala Azar
Miltefosine for Brazilian Visceral Leishmaniasis
Miltefosine will be administered to Brazilian patients with kala azar
- Trial name
- NCT00378495
- Testing
- Miltefosine: initially 2.5 mg/kg/day for 28 days
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- AB Foundation
Visceral Leishmaniasis
Evaluation of Less Invasive Procedures for Visceral Leishmaniasis Treatment Efficacy Monitoring Test of Cure
Left untreated, visceral leishmaniasis (VL) is fatal. The highest burden of VL worldwide is in eastern Africa where field-adapted diagnostic and test-of-cure tools and treatment are lacking.
- Trial name
- VL-ToC (NCT05426577)
- Testing
- ELISA, LAMP, Cytokine Release Assay
- Where
- Ethiopia
- Volunteers
- 60 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Cutaneous Leishmaniasis
Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis
This study serves to compare the effectiveness of treating cutaneous leishmaniasis with either intravenous sodium stibogluconate or direct heat therapy using the ThermoMed-TM device.
- Trial name
- NCT00884377
- Testing
- Sodium stibogluconate (Pentostam), ThermoMed
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- U.S. Army Medical Research and Development Command
Visceral Leishmaniasis, Chagas Disease
A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects
The purpose of this first-in-human study is to generate the necessary safety, tolerability, and pharmacokinetics (PK) information that will support further clinical development of LXE408 for the treatment of patients with…
- Trial name
- NCT07809919
- Testing
- LXE408, Iohexol
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Leishmania Infantum Disease, Leishmaniasis, Visceral
LEISH-PED: Study on Leishmaniasis in Children
Leishmaniasis is an infection caused by Leishmania parasites. In children, it can affect the skin or internal organs. Diagnosis may be delayed because the signs and symptoms can be similar to those of other conditions.
- Conditions
- Leishmania Infantum Disease, Leishmaniasis, Visceral, Leishmaniasis, Cutaneous, Leishmaniasis, Mucocutaneous
- Trial name
- LEISH-PED (NCT07504757)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Meyer Children's Hospital IRCCS
Visceral Leishmaniasis
Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis
The study is designed to determine the use of delivering point of care, rapid diagnosis with rK39 and treatment with AmBisome single dose of 10 mg/kg when administrated in the Primary Health Center (PHC) settings with regard to…
- Trial name
- NCT01566552
- Testing
- AMBISOME
- Where
- India
- Volunteers
- 1,300 people
- Sponsor
- Banaras Hindu University
Skin Diseases
Evaluation of CL Detect™ Rapid Test to Detect Cutaneous Leishmaniasis
This study is a single-site trial assessing the specificity of CL Detect™ Rapid Test versus the gold standard for Leishmania diagnosis in the US which is microscopic identification of Leishmania amastigotes in a stained lesion…
- Trial name
- NCT01865032
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- U.S. Army Medical Research and Development Command
Old World Cutaneous Leishmaniasis
A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis
This Phase 2 study is to determine whether WR279396 with occlusion (a polyurethane dressing) is more effective than WR279396 without occlusion for once daily treatment.
- Trial name
- NCT01536795
- Testing
- WR279,396 with Tegaderm Dressing, WR 279,396 with Gauze and Tape Dressing
- Where
- Tunisia
- Volunteers
- 48 people
- Sponsor
- U.S. Army Medical Research and Development Command
Visceral Leishmaniasis
A Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-Azar
The purpose of this study is: 1. To evaluate the Safety and Efficacy of four different short-course regimens of Amphotericin B emulsion in treatment of Kala-azar (visceral leishmaniasis) subjects who are either treatment naive or…
- Trial name
- NCT00497601
- Testing
- Amphotericin B fat emulsion in visceral leishmaniasis, Amphotericin B fat emulsion, Amphotericin B in fat emulsion
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Banaras Hindu University
Cutaneous Leishminiasis
Comparison of Intralesional Glucantime With and Without Fractional CO₂ Laser in Adults With Cutaneous Leishmaniasis
Cutaneous leishmaniasis is a common parasitic skin disease causing chronic ulcerative lesions and scarring. Intralesional meglumine antimoniate (Glucantime) is a widely used treatment; however, healing may be prolonged and…
- Trial name
- NCT07652021
- Testing
- Meglumine Antimoniate, Fractional CO₂ laser
- Where
- Pakistan
- Volunteers
- 150 people
- Sponsor
- Combined military hospital Peshawar
Brucelloses, Epidemic Hemorrhagic Fever
Real World Study of Classic Infectious Disease
This study aimed to collect and analyze clinical specimens of patients with classic infectious diseases in the real world. To investigate the epidemiological distribution of classic infectious diseases (brucellosis, epidemic…
- Conditions
- Brucelloses, Epidemic Hemorrhagic Fever, Kala-Azar
- Trial name
- NCT04020536
- Testing
- Antibiotics
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Huashan Hospital